SEC Form 4	
------------	--

[]

FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
OMB Number: 3235-0

OMB Number:	3235-0287
Estimated average bur	den 0.5
hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 103
or Section 20(b) of the Investment Company, Act of 1040	Filed pursuant to Section 10(a) of the Securities Exchange Act of 195
	or Section 30(h) of the Investment Company Act of 1940

of Reporting Per	son*	2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
t) (First) (Middle)		ACAD]	X	Director	10% Owner					
		3. Date of Earliest Transaction (Month/Day/Year) 10/12/2023		Officer (give title below)	Other (specify below)					
		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	6. Individual or Joint/Group Filing (Check Appli Line)						
		-	X	Form filed by One Reporting Person						
CA	92130			Form filed by More the Person	an One Reporting					
State)	(Zip)	Rule 10b5-1(c) Transaction Indication								
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								
	First)	ARMACEUTICALS INC. O REAL, SUITE 400 CA 92130	ACADIA PHARMACEUTICALS INC [ACAD] First) (Middle) ARMACEUTICALS INC. O REAL, SUITE 400 CA 92130 State) (Zip) Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant	ACADIA PHARMACEUTICALS INC [ACAD] (Check X First) (Middle) ARMACEUTICALS INC. 3. Date of Earliest Transaction (Month/Day/Year) O REAL, SUITE 400 4. If Amendment, Date of Original Filed (Month/Day/Year) CA 92130 State) (Zip)	ACADIA PHARMACEUTICALS INC [ACAD] (Check all applicable) First) (Middle) ARMACEUTICALS INC. O REAL, SUITE 400 3. Date of Earliest Transaction (Month/Day/Year) (Check all applicable) X Director O REAL, SUITE 400 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filin Line) X Form filed by One Re Form filed by More th Person State) (Zip) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plar					

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	10/12/2023		М		4,381	Α	(1)	4,381	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) Disp of (I	oosed D) tr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(1)	10/12/2023		М			4,381	(2)	(2)	Common Stock	4,381	\$0.00	4,381	D	

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

2. The restricted stock units shall vest in two equal annual installments commencing on the first anniversary of the grant date.

Remarks:

/s/ Austin D. Kim, Attorney-in-Fact 10/16/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.